Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Phase 2 Recruiting 66 enrolled Guangdong Association of Clinical Trials Guangdong Provincial People's Hospital · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We design this trial to evaluate the safety and efficacy of Serplulimab plus chemotherapy in SCLC transformed from EGFR-mutated NSCLC after treatment.

Timeline

Start: 2023-07-07
Primary completion: 2026-06-30
Completion: 2026-12-31

Publications

Huang J, Zhang XH, Cai Y, Yang D, Shi J, Xing P, Xu T, Wu L, Su W, Xu R, Wei T, Chen HJ, Yang JJ. Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study. Clin Oncol (R Coll Radiol). 2024 Jan;36(1):39-45. doi: 10.1016/j.clon.2023.11.030. Epub 2023 Nov 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Etoposide	Small molecule	100 mg/m2	Intravenous
Subject	Serplulimab	Monoclonal antibody	300 mg	Intravenous

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Summary

Timeline

Publications

Drugs

Indications